Dendreon's Provenge faces commercial challenge after EU nod
This article was originally published in Scrip
Executive Summary
Dendreon's personalized prostate cancer immunotherapy Provenge has been approved for marketing in the European Union. The decision was expected after the European Medicines Agency's CHMP granted the therapy a positive opinion in June (scripintelligence.com, 28 June 2013).